Home Health Care History of Advanced Accelerator Application SA (ADR) (NASDAQ:AAAP) Trade

History of Advanced Accelerator Application SA (ADR) (NASDAQ:AAAP) Trade


Intraday Info: Advanced Accelerator Application SA (ADR) (NASDAQ:AAAP) locked on 01/02/2017 at $32.94. It has average volume 576. The company has EPS -0.65 and according to analysts next quarter EPS and next year estimate EPS will -0.32 and -0.54 respectively. Profit Margin of AAAP -16.70% and it total income 18.60 million.

Ownership Summary: Advanced Accelerator Application SA (ADR) has total institutional ownership 10.37% while its total outstanding shares 79 millions that’s value of holdings $264 million.

Active Positions: In the latest year, AAAP 17 holders have raised its positions while it contains total 2,020,454 shares. And the strength of reduced positions holders and held positions holders are 7 and 264,885 respectively.

New and Sold Out Positions: In AAAP force of new positions holders 10 and it has total shares 91,000. And force of sold out positions holders 2 and it has 14 shares.

Comparison with Other Company: The Market Value of AAAP is $1M below from AbbVie Inc. market value which is $98M. Current Last Sale of AAAP is $32.94 below from AbbVie Inc. current last sale which is $60.89.

Advanced Accelerator Application declared that the new England magazine of drugs posted the outcomes of the NETTER-1 segment III take a look at comparing efficacy and safety of Lutathera® (lutetium-177 dotatate), an investigational drug, in sufferers with advanced, revolutionary somatostatin receptor-positive midgut neuroendocrine tumors (“NETs”).

In this take a look at, the number one endpoint become development-free survival (PFS). Secondary endpoints covered objective response rate (ORR), universal survival, safety, and tolerability. The NETTER-1 examine met its number one endpoint with the aid of demonstrating that remedy with Lutathera turned into related to a statistically noteworthyand clinically meaningful 79% reduction in danger of sickness progression or loss of life as comparison to remedy with a excessive dose (60 mg) of Octreotide LAR (risk ratio 0.21, 95% confidence c language: zero.13-zero.33; p<zero.0001). The anticipated PFS rate at month 20 turned into sixty five.2% (ninety five% self belief interval: 50.zero-seventy six.8) in the Lutathera® arm and 10.eight% (ninety five% confidence c language: three.five-23.0) inside the manage arm. Median PFS was 8.4 months inside the manipulate arm, and had no longer but been reached within the Lutathera arm.